vs
ANGIODYNAMICS INC（ANGO）与MERIT MEDICAL SYSTEMS INC（MMSI）财务数据对比。点击上方公司名可切换其他公司
MERIT MEDICAL SYSTEMS INC的季度营收约是ANGIODYNAMICS INC的5.0倍（$393.9M vs $79.4M）。MERIT MEDICAL SYSTEMS INC净利率更高（9.6% vs -8.0%，领先17.6%）。MERIT MEDICAL SYSTEMS INC同比增速更快（10.9% vs 9.0%）。MERIT MEDICAL SYSTEMS INC自由现金流更多（$74.0M vs $4.2M）。过去两年MERIT MEDICAL SYSTEMS INC的营收复合增速更高（10.3% vs 2.8%）
AngioDynamics是一家全球医疗技术企业，专注于研发、生产及销售微创医疗设备，核心产品覆盖血管通路、外科消融、肿瘤治疗等领域，面向北美、欧洲、亚太地区的医院、门诊手术中心及各类医疗机构提供服务。
梅里特医疗系统公司是一家全球性医疗设备企业，设计、生产和销售适用于心脏病学、放射学、肿瘤学、内窥镜及重症监护领域的介入和诊断产品，为全球医院及医疗机构提供微创医疗解决方案，助力提升患者疗效和临床操作效率。
ANGO vs MMSI — 直观对比
营收规模更大
MMSI
是对方的5.0倍
$79.4M
营收增速更快
MMSI
高出1.9%
9.0%
净利率更高
MMSI
高出17.6%
-8.0%
自由现金流更多
MMSI
多$69.8M
$4.2M
两年增速更快
MMSI
近两年复合增速
2.8%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $79.4M | $393.9M |
| 净利润 | $-6.3M | $38.0M |
| 毛利率 | 56.4% | 49.6% |
| 营业利润率 | -7.7% | 13.8% |
| 净利率 | -8.0% | 9.6% |
| 营收同比 | 9.0% | 10.9% |
| 净利润同比 | 40.9% | 36.0% |
| 每股收益（稀释后） | $-0.15 | $0.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANGOMMSI
| Q4 25 | $79.4M | $393.9M | ||
| Q3 25 | $75.7M | $384.2M | ||
| Q2 25 | $80.2M | $382.5M | ||
| Q1 25 | $72.0M | $355.4M | ||
| Q4 24 | $72.8M | $355.2M | ||
| Q3 24 | $67.5M | $339.8M | ||
| Q2 24 | $71.0M | $338.0M | ||
| Q1 24 | $75.2M | $323.5M |
净利润ANGOMMSI
| Q4 25 | $-6.3M | $38.0M | ||
| Q3 25 | $-10.9M | $27.8M | ||
| Q2 25 | $-6.0M | $32.6M | ||
| Q1 25 | $-4.4M | $30.1M | ||
| Q4 24 | $-10.7M | $27.9M | ||
| Q3 24 | $-12.8M | $28.4M | ||
| Q2 24 | $-13.4M | $35.7M | ||
| Q1 24 | $-187.7M | $28.2M |
毛利率ANGOMMSI
| Q4 25 | 56.4% | 49.6% | ||
| Q3 25 | 55.3% | 48.5% | ||
| Q2 25 | 52.7% | 48.2% | ||
| Q1 25 | 54.0% | 48.4% | ||
| Q4 24 | 54.8% | 48.7% | ||
| Q3 24 | 54.4% | 46.4% | ||
| Q2 24 | 54.3% | 47.7% | ||
| Q1 24 | 47.7% | 46.9% |
营业利润率ANGOMMSI
| Q4 25 | -7.7% | 13.8% | ||
| Q3 25 | -14.1% | 11.1% | ||
| Q2 25 | -7.2% | 12.3% | ||
| Q1 25 | -13.9% | 11.5% | ||
| Q4 24 | -15.2% | 10.3% | ||
| Q3 24 | -19.4% | 11.0% | ||
| Q2 24 | -20.4% | 13.6% | ||
| Q1 24 | -265.9% | 11.1% |
净利率ANGOMMSI
| Q4 25 | -8.0% | 9.6% | ||
| Q3 25 | -14.4% | 7.2% | ||
| Q2 25 | -7.5% | 8.5% | ||
| Q1 25 | -6.1% | 8.5% | ||
| Q4 24 | -14.7% | 7.9% | ||
| Q3 24 | -19.0% | 8.4% | ||
| Q2 24 | -18.9% | 10.6% | ||
| Q1 24 | -249.7% | 8.7% |
每股收益（稀释后）ANGOMMSI
| Q4 25 | $-0.15 | $0.64 | ||
| Q3 25 | $-0.26 | $0.46 | ||
| Q2 25 | $-0.15 | $0.54 | ||
| Q1 25 | $-0.11 | $0.49 | ||
| Q4 24 | $-0.26 | $0.46 | ||
| Q3 24 | $-0.31 | $0.48 | ||
| Q2 24 | $-0.35 | $0.61 | ||
| Q1 24 | $-4.67 | $0.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.6M | $446.4M |
| 总债务越低越好 | — | $734.0M |
| 股东权益账面价值 | $176.3M | $1.6B |
| 总资产 | $269.7M | $2.7B |
| 负债/权益比越低杠杆越低 | — | 0.46× |
8季度趋势，按日历期对齐
现金及短期投资ANGOMMSI
| Q4 25 | $41.6M | $446.4M | ||
| Q3 25 | $38.8M | $392.5M | ||
| Q2 25 | $55.9M | $341.8M | ||
| Q1 25 | $44.8M | $395.5M | ||
| Q4 24 | $54.1M | $376.7M | ||
| Q3 24 | $55.0M | $523.1M | ||
| Q2 24 | $76.1M | $636.7M | ||
| Q1 24 | $78.5M | $581.9M |
总债务ANGOMMSI
| Q4 25 | — | $734.0M | ||
| Q3 25 | — | $732.9M | ||
| Q2 25 | — | $731.8M | ||
| Q1 25 | — | $730.7M | ||
| Q4 24 | — | $729.6M | ||
| Q3 24 | — | $750.5M | ||
| Q2 24 | $0 | $801.3M | ||
| Q1 24 | — | $800.1M |
股东权益ANGOMMSI
| Q4 25 | $176.3M | $1.6B | ||
| Q3 25 | $178.9M | $1.5B | ||
| Q2 25 | $183.0M | $1.5B | ||
| Q1 25 | $185.9M | $1.4B | ||
| Q4 24 | $186.8M | $1.4B | ||
| Q3 24 | $196.6M | $1.3B | ||
| Q2 24 | $205.6M | $1.3B | ||
| Q1 24 | $218.7M | $1.2B |
总资产ANGOMMSI
| Q4 25 | $269.7M | $2.7B | ||
| Q3 25 | $265.6M | $2.6B | ||
| Q2 25 | $280.1M | $2.6B | ||
| Q1 25 | $285.4M | $2.5B | ||
| Q4 24 | $291.6M | $2.4B | ||
| Q3 24 | $293.6M | $2.4B | ||
| Q2 24 | $317.7M | $2.4B | ||
| Q1 24 | $324.8M | $2.3B |
负债/权益比ANGOMMSI
| Q4 25 | — | 0.46× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.49× | ||
| Q1 25 | — | 0.51× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | — | 0.57× | ||
| Q2 24 | 0.00× | 0.62× | ||
| Q1 24 | — | 0.65× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.7M | $98.5M |
| 自由现金流经营现金流 - 资本支出 | $4.2M | $74.0M |
| 自由现金流率自由现金流/营收 | 5.3% | 18.8% |
| 资本支出强度资本支出/营收 | 0.5% | 6.2% |
| 现金转化率经营现金流/净利润 | — | 2.59× |
| 过去12个月自由现金流最近4个季度 | $-9.3M | $215.7M |
8季度趋势，按日历期对齐
经营现金流ANGOMMSI
| Q4 25 | $4.7M | $98.5M | ||
| Q3 25 | $-15.9M | $75.0M | ||
| Q2 25 | $18.8M | $83.3M | ||
| Q1 25 | $-13.2M | $40.6M | ||
| Q4 24 | $2.5M | $68.7M | ||
| Q3 24 | $-18.3M | $47.3M | ||
| Q2 24 | $5.0M | $68.5M | ||
| Q1 24 | $-12.5M | $36.2M |
自由现金流ANGOMMSI
| Q4 25 | $4.2M | $74.0M | ||
| Q3 25 | $-16.6M | $52.5M | ||
| Q2 25 | $18.0M | $69.6M | ||
| Q1 25 | $-15.0M | $19.5M | ||
| Q4 24 | $1.7M | $65.3M | ||
| Q3 24 | $-19.3M | $38.0M | ||
| Q2 24 | $4.4M | $57.9M | ||
| Q1 24 | $-13.1M | $24.5M |
自由现金流率ANGOMMSI
| Q4 25 | 5.3% | 18.8% | ||
| Q3 25 | -22.0% | 13.7% | ||
| Q2 25 | 22.5% | 18.2% | ||
| Q1 25 | -20.8% | 5.5% | ||
| Q4 24 | 2.3% | 18.4% | ||
| Q3 24 | -28.7% | 11.2% | ||
| Q2 24 | 6.2% | 17.1% | ||
| Q1 24 | -17.5% | 7.6% |
资本支出强度ANGOMMSI
| Q4 25 | 0.5% | 6.2% | ||
| Q3 25 | 1.0% | 5.8% | ||
| Q2 25 | 1.0% | 3.6% | ||
| Q1 25 | 2.5% | 5.9% | ||
| Q4 24 | 1.1% | 1.0% | ||
| Q3 24 | 1.6% | 2.8% | ||
| Q2 24 | 0.8% | 3.1% | ||
| Q1 24 | 0.8% | 3.6% |
现金转化率ANGOMMSI
| Q4 25 | — | 2.59× | ||
| Q3 25 | — | 2.70× | ||
| Q2 25 | — | 2.56× | ||
| Q1 25 | — | 1.35× | ||
| Q4 24 | — | 2.46× | ||
| Q3 24 | — | 1.66× | ||
| Q2 24 | — | 1.92× | ||
| Q1 24 | — | 1.28× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANGO
| Med Device | $37.2M | 47% |
| Med Tech | $30.4M | 38% |
| Other | $11.8M | 15% |
MMSI
| Other | $154.6M | 39% |
| Peripheral Intervention | $93.2M | 24% |
| Cardiac Intervention | $50.2M | 13% |
| OEM | $42.6M | 11% |
| Custom Procedural Solutions | $33.1M | 8% |
| Endoscopy Segment | $20.1M | 5% |
